Related references
Note: Only part of the references are listed.Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review
Akisha Glasgow et al.
BREAST CANCER (2021)
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2-early breast cancer
Laurence Slembrouck et al.
MODERN PATHOLOGY (2021)
Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools
Julia Foldi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
N. Lynn Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer
Jinani Jayasekera et al.
JNCI CANCER SPECTRUM (2019)
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer
Jinani Jayasekera et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model
Clyde B. Schechter et al.
MEDICAL DECISION MAKING (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer
Jinani Jayasekera et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Charles E. Geyer et al.
NPJ BREAST CANCER (2018)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Breast cancer statistics, 2017, racial disparity in mortality by state
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study
Valentina I. Petkov et al.
NPJ BREAST CANCER (2016)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits
Iris Lansdorp-Vogelaar et al.
ANNALS OF INTERNAL MEDICINE (2014)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
David M. Eddy et al.
MEDICAL DECISION MAKING (2012)
Factors Influencing Treatment Recommendations in Node-Negative Breast Cancer
Elisabeth Edstrom Elder et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California
Marilyn L. Kwan et al.
CANCER CAUSES & CONTROL (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VH Murthy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Development of a comorbidity index using physician claims data
CN Klabunde et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
Share Paper
